News & Events:BLUE

Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session

  Don't forget to check out our premarket coverage here .

Gainers  

bluebird bio Inc: * BLUEBIRD BIO REPORTS SECOND QUARTER 2022 FINANCIAL RESULTS AND HIGHLIGHTS OPERATIONAL PROGRESS. * BETI-CEL FOR BETA-THALASSEMIA PDUFA GOAL DATE IS SET FOR AUGUST 19, 2022. * ELI-CEL FOR CEREBRAL ADRENOLEUKODYSTROPHY PDUFA GOAL DATE IS SET FOR SEPTEMBER 16, 2022.

- - eli-cel for cerebral adrenoleukodystrophy PDUFA goal date is set for September 16, 2022 - - Ended quarter with $218M in restricted cash, cash and cash equivalents and marketable securities - SOMERVILLE, Mass---- bluebird bio, Inc. today reported financial results and business highlights for the second quarter ended June 30, 2022, and shared recent operational progress.

Over the past 3 months, 4 analysts have published their opinion on bluebird bio stock. These 4 analysts have an average price target of $4.0 versus the current price of bluebird bio at $4.0481, implying downside. Below is a summary of how these 4 analysts rated bluebird bio over the past 3 months. This current average has not changed from the previous average price target.

For Transocean Ltd, Capital One upgraded the previous rating of Equal-Weight to Overweight. Raymond James upgraded the previous rating for Tricon Residential Inc from Outperform to Strong Buy. Credit Suisse upgraded the previous rating for BanColombia SA from Neutral to Outperform. Raymond James upgraded the previous rating for bluebird bio Inc from Market Perform to Outperform.

Regulatory decisions have yet to pick up pace this year. The following treatments received Food and Drug Administration's blessings in July: Horizon Therapeutics Ltd.'s gout treatment Krystexxa got an expanded label to be used in combination with methotrexate.

  This article was generated by Benzinga's automated content engine and reviewed by an editor.

Tesla, Ra Medical Systems And 51 Stocks Moving In Tuesday's Mid-Day Session

  This article was generated by Benzinga's automated content engine and reviewed by an editor.

 Gainers Fujian Blue Hat Interactive Entertainment Technology Ltd. rose 83.8% to $1.3824. Blue Hat Interactive terminated its previously proposed shelf takedown offering.    Losers BIT Mining Limited shares dipped 40.4% to $0.7089 after the company announced a $16 million registered direct offering.  

This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLUEBIRD BIO INC (BLUE): * BLUEBIRD BIO INC (BLUE) - ENTERED INTO EQUITY DISTRIBUTION AGREEMENT WITH GOLDMAN SACHS & CO. LLC, AS OUR SALES AGENT. * BLUEBIRD BIO INC (BLUE) - MAY OFFER, SELL COMMON STOCK HAVING AGGREGATE OFFERING PRICE OF UP TO $75.0 MILLION FROM TIME TO TIME THROUGH OR TO THE SALES AGENT Source text for Eikon: [https://bit.ly/3zYqkDk] Further company coverage:

U.S. stocks pared gains midway through trading, with the Dow Jones dropping around 100 points on Friday. The Dow traded down 0.35% to 29,821.15 while the NASDAQ rose 0.97% to 10,749.10. The S&P also fell, dropping, 0.16% to 3,660.85. Also check this: 3 Stocks Under $1 Insiders Are Buying Leading and Lagging Sectors Health care shares jumped by 0.4% on Friday.

 Gainers Revlon, Inc. gained 81.5% to $3.54 following a report suggesting Reliance Industries is considering buying out the company, which recently filed for bankruptcy.    Losers Renovare Environmental, Inc dipped 73.5% to $0.0450.